A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease

Radium-223 dichloride (radium-223) mimics calcium and emits high-energy, short-range alpha-particles resulting in an antitumor effect on bone metastases. This open-label, phase IIa nonrandomized study investigated safety and short-term efficacy of radium-223 in breast cancer patients with bone-domin...

Descripción completa

Detalles Bibliográficos
Autores principales: Coleman, Robert, Aksnes, Anne-Kirsti, Naume, Bjørn, Garcia, Camilo, Jerusalem, Guy, Piccart, Martine, Vobecky, Nancy, Thuresson, Marcus, Flamen, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025174/
https://www.ncbi.nlm.nih.gov/pubmed/24728613
http://dx.doi.org/10.1007/s10549-014-2939-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4025174/
https://www.ncbi.nlm.nih.gov/pubmed/24728613
http://dx.doi.org/10.1007/s10549-014-2939-1

Ejemplares similares